|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
The results indicate that there is no or minimal influence of the PAI-1 gene on either PAI-1 levels or the development of diabetic retinopathy in patients with diabetes mellitus.
|
7974340 |
1994 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
Elevated plasminogen activator inhibitor-1 may contribute to vascular disease in diabetes mellitus.
|
8960834 |
1996 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
In a logistic regression analysis controlled for age, sex, BMI, and duration of diabetes, any retinopathy was significantly associated with fasting plasma glucose concentrations (P < 0.05), 2-h postload glucose (P = 0.02), and HbA1c (P = 0.008), but not with PAI-1 activity (P = 0.48).
|
9250459 |
1997 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy1.
|
9844142 |
1998 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
A multiple linear regression model with independent variables (age, body-mass index, total cholesterol level, triglyceride level, ACE I/D genotype, and PAI-1 genotype due to a single guanine I/D polymorphism in the PAI-1 gene) demonstrated that the triglyceride level (P = 0.0059) and ACE I/D genotype (P = 0.0372) were independent predictors of plasma PAI-1 antigen levels in a subset of the subjects without diabetes mellitus that were not taking lipid-lowering drugs.
|
10759003 |
2000 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
GeneticVariation |
BEFREE |
The PAI-1 and ACE (D/I) gene polymorphisms were examined in a cohort of Chinese type 2 diabetic patients who had diabetes for an average of 14 years.
|
10652041 |
2000 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
To evaluate whether hyperglycaemia in two lean patients with primary severe insulin resistance due to insulin receptor (IR) mutations and diabetes mellitus could be reduced by supplement of rosiglitazone for 180 days and secondary, to evaluate the effects on plasma NEFA, TG, Apo B, PAI-1 and serum insulin.
|
11887975 |
2001 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
The results of the present study suggest that LDL and VLDL from patients with DM reduce the generation of tPA and increase PAI-1 production through the activation of the PAI-1 promoter in vascular EC.
|
11788661 |
2002 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
Concentrations in blood of plasminogen activator inhibitor type 1 (PAI-1) and circulating free (non-esterified) fatty acids (FFA) are increased in diabetes and may accelerate atherosclerosis.
|
12669679 |
2002 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
GeneticVariation |
BEFREE |
Interaction between genotype and diabetes status was estimated for nine CVD risk factors [body fat mass (FAT), body mass index (BMI), high-density lipoprotein cholesterol (HDL-C), log-transformed fibrinogen, log-transformed triglycerides, log-transformed urinary albumin : creatinine ratio (LACR), plasminogen activator inhibitor 1 (PAI-1), systolic blood pressure (SBP), and waist-to-hip ratio (WHR)], using a maximum likelihood variance decomposition technique.
|
12673782 |
2003 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
In 45/112 patients without the established risk factors for RVO (hyper-tension, hypercholesterolemia and diabetes) or characteristics known to be associated to increased PAI-1 activity (overweight, hypertriglyceridemia, and smoking habit) the contemporary presence of ACE DD and PAI-1 4G4G genotype was significantly associated with a risk for RVO (OR = 8.26, 95% CI 1.18-57.92; p = 0.034).
|
15213845 |
2004 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
Elevated levels of plasminogen activator inhibitor-1 (PAI-1) are associated with myocardial infarction and stroke, especially in patients with diabetes.
|
15956119 |
2005 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
Its effects on ROS production, AP-1 activity, plasminogen activator inhibitor 1 (PAI-1) gene expression, and cellular proliferation and migration were measured in response to high glucose and angiotensin II (Ang II) concentrations, two major factors in the pathogenesis of atherosclerosis in patients with diabetes and hypertension.
|
15827742 |
2005 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
Increased flux through HBP is required and sufficient for some of the metabolic effects of sustained, increased glucose flux, which promotes the complications of diabetes, e.g., diminished expression of sarcoplasmic reticulum Ca(2+)-ATPase in cardiomyocytes and induction of TGF-beta and plasminogen activator inhibitor-1 in vascular smooth muscle cells, mesangial cells, and aortic endothelial cells.
|
16339923 |
2006 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
Elevated PAI-1 levels may be associated with an increased risk for diabetes as a marker for underlying endothelial dysfunction rather than by a direct effect of genetically mediated elevated levels.
|
16855181 |
2006 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
Patients most likely to benefit from PAI-1 inhibition would be those at high risk for vascular events where PAI-1 is elevated, such as is observed in obesity, diabetes and the metabolic syndrome.
|
17896948 |
2007 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
Circulating plasminogen activator inhibitor-1 levels are elevated at an early stage of impaired glucose tolerance, resulting in diabetes and metabolic syndrome.
|
18160587 |
2008 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
Plasminogen activator inhibitor type 1 (PAI-1), produced partly from liver is a risk factor for macrovascular and microvascular complications of diabetes.
|
18700166 |
2008 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
Since TGF-beta1 is well known to stimulate the PAI-1 promoter, we suggest that TGF-beta1 and PAI-1 together constitute a positive feedback loop in the development of renal fibrosis in diabetes.
|
19786738 |
2009 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
Increased levels of PAI-1 and glycated low-density lipoprotein (glyLDL) were detected in patients with diabetes.
|
20630999 |
2010 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
Biomarker |
BEFREE |
Myocardial mRNA levels of interleukin-6, tumor necrosis factor-α, plasminogen activator inhibitor-1, angiotensin type 1 receptor, angiotensinogen, NADPH oxidase subunits (p47(phox), gp91(phox)), glutathione peroxidase-3. and connective tissue growth factor were increased in CRP/DM compared with Wt/DM.
|
21519150 |
2011 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
GeneticVariation |
BEFREE |
Plasminogen activator inhibitor-1 5G/5G genotype is a protecting factor preventing posttransplant diabetes mellitus.
|
21070757 |
2011 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
GeneticVariation |
BEFREE |
MTHFRA1298C and PAI-1 deletions were most frequent genetic variants in risk groups for MI in patients with diabetes mellitus (value of odds ratio sequentially [OR] = 3.79, p = 0.06 and [OR] = 5 × 10(8), p = 0.000).
|
22752805 |
2012 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
AlteredExpression |
BEFREE |
To address this, we used type 1 diabetes mouse model induced by streptozocin to be hyperglycemic for 8 weeks, and isolated endothelial cells that were used either freshly after isolation or after 2 to 3-week cell culture in normoglycemic conditions. mRNA expression profiling in diabetic mouse endothelial cells revealed significant and persistent up-regulation of Serpine1 encoding PAI-1, the hypo-fibrinolytic mediator leading to thrombotic diseases in diabetes, along with Rock2, Fn1 and Ccl2, whereas only Serpine 1 was persistently elevated in high glucose-treated mouse endothelial cells.
|
23454124 |
2013 |
|
SERPINE1
|
Diabetes Mellitus
|
0.300 |
GeneticVariation |
BEFREE |
Our meta-analyses suggest that the PAI-1 -675 4G/5G polymorphism might not be a risk factor for DM, DN, DR or diabetic CAD risk in the populations investigated.
|
24223897 |
2013 |